AARTI PHARMALABS LIMITED Fair Value
AARTIPHARM · Healthcare · Current price ₹864.35
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹222 | 9% ROE fading to 13% over ~3 yrs, on ₹234 book |
| Relative P/E | ₹697 | EPS × 36.2 peer-median P/E |
| Graham floor | ₹319 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹740 | Street consensus 12-month target price |
Is AARTI PHARMALABS LIMITED undervalued?
DocStoX estimates the fair value of AARTI PHARMALABS LIMITED at ₹437 per share, versus the current market price of ₹864. That puts the stock about -49.4% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹222), Relative P/E (₹697), Graham floor (₹319), Analyst target (₹740). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹222 (bear) to ₹437 (base) to ₹740 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on AARTI PHARMALABS LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.